1 Association of Age-Related Macular Degeneration With Mortality: A Propensity 2 Score-Matched Analysis

3

4 **Running Title:** AMD and mortality

5

6 **Authors**

7 Yifan Chen, BM BCh^{1,2}

8 Yueye Wang, MD³

9 Xianwen Shang, PhD¹

10 Wei Wang, MD PhD³

11 Zhuoting Zhu, MD PhD¹

12

13 **Affiliations**

14 1. Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial
15 People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080,
16 China

17 2. John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,
18 UK.

19 3. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
20 University, Guangzhou, China.

21

22 **Word Count:** Abstract, 248; Whole paper, 1789.

23 **Tables:** 2

24

25 **Corresponding Author**

26 Zhuoting Zhu, MD PhD

27 Email: zhuoting_zhu@hotmail.com

28 Wei Wang, MD PhD

29 Email: zoc_wangwei@yahoo.com

30

31 **Synopsis**

32 Late macular degeneration independently predicted higher cardiovascular disease mortality.
33 Any, early and late age-related macular degeneration were associated with higher all-cause
34 mortality and mortality due to causes other than cardiovascular disease or cancer.

35

36 **Abstract**

37 **Purpose:** To investigate the association between age-related macular degeneration (AMD)
38 and 10-year all-cause and cause-specific mortality using a large-scale population-based
39 sample.

40 **Methods:** Data from the 2005-2008 cycles of the National Health and Nutrition
41 Examination Survey were used to assess the risk of mortality in relation to AMD in a
42 propensity score-matched cohort. AMD status was assessed by retinal images with the
43 standardized grading scheme. Mortality data until 31st December 2015 were derived from
44 mortality archives. Cox proportional hazards regression models were used to estimate
45 hazard ratios (HRs) and 95% confidence intervals (CIs) for survival.

46 **Results:** A total of 4691 participants were included. After a median follow-up of 8.42 (IQR:
47 7.58-9.67) years, 698 participants died. Participants with any AMD had an increased risk of
48 all-cause mortality (HR, 2.02; 95% CI, 1.37-2.98). Similar results were observed for early
49 (HR, 1.93; 95% CI, 1.31-2.85) and late AMD (HR, 4.29; 95% CI, 2.10-8.79). For
50 cause-specific mortality, any (HR, 2.17; 95% CI, 1.39-3.39), early (HR, 2.18; 95% CI,
51 1.36-3.51), and late AMD (HR, 3.95; 95% CI, 1.65-9.46) were associated with significantly
52 higher mortality due to causes other than cardiovascular disease (CVD) or cancer. Late
53 AMD independently predicted a higher risk of CVD mortality (HR, 2.48; 95% CI,
54 1.32-4.65).

55 **Conclusions:** The current study showed that any, early, and late AMD were associated
56 with increased risks of all-cause mortality and mortality due to causes other than CVD or
57 cancer. In addition, we found that late AMD was associated with increased risks of CVD

58 mortality.

59

60

61 **Keywords:** age-related macular degeneration, all-cause mortality, cause-specific mortality.

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89 **Introduction**

90 Age-related macular degeneration (AMD) is one of the leading causes of visual impairment
91 and blindness worldwide.¹ The number of people with AMD globally is projected to
92 increase to 288 million in 2040.² In the United States, the number of people with AMD is
93 estimated to reach 2.95 million in 2020.³ As the population ages, the prevalence of AMD is
94 likely to increase further, leading to significant economic and societal costs.⁴

95

96 Accumulating evidence has suggested that AMD is an independent risk factor for all-cause
97 mortality.⁵⁻¹⁰ However, the results for its association with cause-specific mortality remain
98 inconsistent.¹¹⁻²⁰ Some studies have reported that AMD was associated with an increased
99 risk of CVD mortality,^{5,6,8} while others did not find any significant association between
100 AMD and CVD mortality.^{11,12,19} Investigators have previously hypothesized that the similar
101 risk profile shared by AMD and CVD²¹⁻²³, as well as the potential thromboembolic events
102 secondary to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment^{24,25}
103 may increase the risk of CVD mortality among patients with AMD.

104

105 Our previous study published in 2018 found that only late AMD increased the risk of
106 5-year all-cause and non-CVD non-cancer mortality, while no significant association was
107 found between AMD and CVD mortality using data from the National Health and Nutrition
108 Examination Survey (NHANES).²⁶ The availability of 10-year mortality data empowers us
109 with longer follow-up and more statistical power to investigate the long-term mortality
110 among patients with AMD.

111

112 The propensity score reflects the probability of being exposed based on baseline
113 covariates²⁷. As a popular method used for controlling confounders, propensity score
114 matching works with prevalence in giving unbiased estimate in observational studies with
115 multiple covariates and rare outcome^{28,29}. Thus, in this study, propensity score matching
116 was employed instead of conventional parsimonious regression models by matching
117 participants with similar distribution of confounders, to maximum eliminate potential bias.

118

119 Therefore, we aim to investigate the association of AMD with 10-year all-cause and
120 cause-specific mortality using a propensity score-matched method.

121

122 **Methods**

123 **Sample and Population**

124 The NHANES is conducted by the National Center for Health Statistics (NCHS) of the
125 Centers for Disease Control and Prevention. It uses stratified multistage sampling methods,
126 described in detail elsewhere.³⁰ Briefly, all participants completed health-related interviews
127 and examinations in each cycle of the NHANES, which was conducted every two years. In
128 this survey analysis, we analyzed data from the 2005-2008 cycles of the NHANES.
129 NHANES protocols were reviewed and approved by the NCHS research ethics review
130 committee and all participants provided written informed consent.

131

132 **AMD Identification**

133 During the 2005-2008 cycles of NHANES, retinal images were collected from participants
134 aged 40 years and older using an ophthalmic digital imaging system (CR6-45NM; Canon
135 USA, Inc) and digital camera (EOS 10D; Canon USA, Inc). Fundus images were graded at
136 the University of Wisconsin, Madison, according to the modified Wisconsin Age-Related
137 Maculopathy Grading Classification Scheme.^{31,32} Early AMD was defined as signs of
138 drusen with a grid area of more than a 500 μm circle and/or pigmentary abnormalities. Late
139 AMD was defined as the presence of exudative or geographic atrophy signs. The AMD
140 status was decided based on the more severely affected eye.

141

142 **Mortality Data**

143 Mortality data were derived from the 2020 public-access linked mortality archives.³³ The
144 International Statistical Classification of Diseases and Related Health Problems, Tenth
145 Revision (ICD-10) codes were used to determine causes of deaths. Codes I00 to I09, I11,
146 I13, and I20 to I51 (diseases of heart) and I60 to I69 (cerebrovascular disease) were defined
147 as death attributable to CVD. ICD-10 codes C00 to C97 were defined as cancer mortality.

Any other causes of death were considered death due to causes other than CVD or cancer. Participants were considered alive if not matched with death certificates. Time to death was counted from baseline to date of death or the 31st of December, 2015, whichever came first.

151

152 **Confounding Variables**

Information on demographics, health-related behaviors, and other characteristics was collected by in-person interviews and examinations. The confounding variables considered in this analysis include age, gender, ethnicity, education, marital status, family income, smoking status, alcohol consumption, diabetes mellitus, hypertension, high cholesterol, body mass index, C-reactive protein level, walking disability, self-rated health status, depressive symptoms, coexisting ocular diseases, history of cardiovascular diseases and history of cancer. Details on how these confounding variables were determined were described in a previous paper.^{26,34-37} The exclusion on confounding factors was done if any one of the factors were missing.

162

163 **Statistical Analysis**

Data from the 2005-2006 and 2007-2008 cycles of NHANES were combined and analysed accounting for the complex and stratified designed based on the NHANES analytic and reporting guidelines.³⁸ In the present analysis, we assessed the risk of mortality in relation to AMD in a propensity score-matched cohort. Logistic regression models were used to create the propensity score and the balance of covariates in models was tested. Inverse probability of treatment weighting method based on the synthesized propensity score was used to match participants with and without AMD. Unpaired t-test and design-adjusted Rao-Scott Pearson χ^2 test were used for the comparison of continuous and categorical variables, respectively. Hazard ratios (HRs) and their 95% confidence interval (95% CI) were estimated by Cox proportional hazards regression models. Sensitivity analyses that excluding the participants with cancer at baseline were further performed to validate the robustness of our findings. All analyses were carried out in Stata (Version 14; Stata Corp, College Station, TX). A P value of less than 0.05 was considered to be significant.

177

178 **Results**

179 **Study Population**

180 After excluding 1193 participants who had missing information on the AMD status and/or
181 survival status, and 913 participants who had missing information on confounding factors,
182 4691 participants were identified. Excluded participants were more likely to be elderly, of
183 female gender, non-Hispanic black and other ethnicities, lower educational level,
184 unmarried status, below poverty line, and lifetime abstainer/former drinker. They also
185 tended to have comorbidities history, coexisting ocular diseases, walking disability, and
186 poorer general health status (Supplement Table 1).

187
188 There were 360 participants with AMD and 4331 participants without AMD. There was no
189 significant difference in baseline characteristics between AMD and non-AMD participants
190 after propensity score matching (Table 1).

191

192 **All-cause mortality**

193 After a median duration of 8.42 (IQR: 7.58-9.67) years, a total of 698 participants died
194 from all causes. After adjustments for confounding factors, the Cox proportional hazards
195 regression model indicated that any AMD was associated with increased all-cause mortality
196 (HR, 2.02; 95% CI, 1.37-2.98). Early AMD (HR, 1.93; 95% CI, 1.31-2.85) and late AMD
197 (HR, 4.29; 95% CI, 2.10-8.79) were also associated with significantly higher all-cause
198 mortality compared to the group without AMD.

199

200 **Cause-specific mortality**

201 Of all deaths, 129, 164, and 405 were attributable to CVD, cancer, and non-CVD
202 non-cancer causes, respectively. After multiple adjustments, Cox proportional hazards
203 regression model showed that any AMD (HR, 2.17; 95% CI, 1.39-3.39), early AMD (HR,
204 2.18; 95% CI, 1.36-3.51) and late AMD (HR, 3.95; 95% CI, 1.65-9.46) were significantly
205 associated with higher risks of mortality due to causes other than CVD or cancer. In the
206 fully adjusted model, we found that late AMD independently predicted a higher risk of
207 CVD mortality (HR, 2.48; 95% CI, 1.32-4.65).

208

209 **Sensitivity analysis**

210 Sensitivity analyses that excluding the participants with cancer at baseline were further
211 performed to validate the robustness of our findings. Similar results were noted
212 (Supplement Table 2).

213

214 **Discussion**

215 The present study showed that any, early and late AMD were significantly associated with
216 increased risks of all-cause mortality and mortality due to causes other than CVD or cancer,
217 which was consistent with our previous study²⁶ with a 5-year follow-up duration. In
218 addition, we found that late AMD is associated with increased CVD mortality.

219

220 Consistent evidence on the association between late AMD and increased risks of all-cause
221 mortality has been reported.^{6,12,26,39,40} Whereas conflicting results were found on the
222 associations of early or any AMD with all-cause mortality.^{6-8,11-13,15,17,20,39} These conflicting
223 results might be due to the heterogeneity in the study population, detection of AMD,
224 statistical methods, and confounding factors adjusted for. The present analysis indicated
225 that any form of AMD was associated with increased risks of mortality, suggesting the
226 presence of AMD might be a biomarker of ageing and frailty. Even though the exact
227 mechanism for the significant association between AMD and mortality remains unclear,
228 growing evidence has indicated some common pathways shared between the ageing
229 process and the pathogenesis of AMD, such as increased oxidative stress and chronic
230 inflammation.⁴¹⁻⁴³

231

232 The present study found that participants with late AMD had significantly higher CVD
233 mortality. Growing evidence has demonstrated a close relationship between AMD and
234 increased CVD mortality.^{5,6,8,11,12,34,44} Two recent systematic reviews found that late AMD
235 was significantly associated with increased CVD mortality with an estimated HR of 1.46
236 and 1.28 respectively.^{39,40} The association between late AMD and CVD mortality might be
237 explained by their common pathogenesis pathways (e.g., local inflammation and oxidative

stress) and risk factors (e.g., age and smoking).^{35,45,46} The ‘hallmark’ of AMD, drusen, closely resembled atherosclerotic plaques in composition.⁴⁶ In addition, the use of anti-VEGF to treat neovascular AMD might also increase CVD risks leading to higher CVD mortality.^{24,25,47,48}

Consistent with previous studies,^{10,11} we also found a strong association between AMD and non-CVD non-cancer mortality. Several hypotheses may explain this. Firstly, participants with AMD may be more generally frail. Secondly, increasing evidence suggested that AMD was significantly associated with neurodegenerative diseases (e.g., Alzheimer’s disease).⁴⁹⁻⁵¹ Last but not least, participants with AMD might be more likely to suffer from functional disabilities and social deprivation due to impaired vision.⁵²⁻⁵⁴

The present study has the advantage of a large-scale nationally sample, long-term follow-up and the use of propensity score matching method to eliminate confounding effects, which could fairly imitate the settings of random clinical trials. Moreover, the high consistency among results of the multiple sensitivity analyses and the primary analysis strongly supported the validity of our findings. Several limitations should be considered. Firstly, the relatively small number of participants with late AMD preventing us from conducting further subgroup analyses. Large-scale studies are needed to corroborate our findings. Secondly, the AMD status being assessed at a single time point, the consecutive trend could only be inferred. Thirdly, though we have included and matched most of the previously established confounders, less precise estimates from propensity scores may be drawn due to potential unmatched baseline characteristics. Last but not the least, the differences in baseline characteristics between excluded participants and included participants might bias the AMD-mortality associations.

Conclusion

In summary, the present study showed that any, early, and late AMD were associated with increased risks of all-cause mortality and mortality due to causes other than CVD or cancer. Furthermore, we also found that late AMD independently predicted a higher risk of CVD

268 mortality. Our results highlight the importance of early detection and management of AMD
 269 as this helps to identify the vulnerable group of patients who have increased long-term
 270 mortality.

271

272 Table 1. Characteristics of Participants With And Without AMD in Propensity Score-Matched Cohorts.

Characteristics	No. (%)		P Value ^a
	Non-AMD	AMD	
Age, yrs			
40-49	1263 (34.9)	24 (43.5)	0.312
50-59	1100 (31.0)	39 (24.2)	
60-69	1084 (18.6)	80 (17.8)	
70-79	644 (11.2)	107 (9.64)	
≥80	240 (4.33)	110 (4.94)	
Gender			
Male	2185 (48.0)	187 (52.5)	0.408
Female	2146 (52.0)	173 (47.5)	
Race			
Non-Hispanic white	2347 (78.4)	258 (84.7)	0.050
Non-Hispanic black	871 (8.96)	31 (4.29)	
Mexican American	689 (5.32)	42 (5.90)	
Other	424 (7.32)	29 (5.16)	
Education			
Less than high school	1210 (17.1)	100 (17.1)	0.996
High school and over	3121 (82.9)	260 (82.9)	
Marital status			
Unmarried and other	1481 (30.2)	169 (23.6)	0.142
Married/with a partner	2850 (69.8)	191 (76.4)	
Poverty income ratio (PIR)			
Below poverty (<1)	640 (8.46)	55 (7.57)	0.723

At or above poverty (≥ 1)	3691 (91.5)	305 (92.4)	
Smoking status			
Never	2057 (48.7)	164 (41.5)	0.292
Former	1376 (30.9)	145 (39.7)	
Current	898 (20.4)	51 (18.8)	
Alcohol consumption			
Lifetime abstainer/former drinker	1025 (19.8)	100 (17.4)	0.588
Current drinker	2362 (55.5)	185 (60.5)	
(≤ 3 drinks/w)			
Current drinker	944 (24.7)	75 (22.1)	
(> 3 drinks/w)			
Diabetes mellitus			
No	3535 (87.0)	299 (89.7)	0.296
Yes	796 (13.0)	61 (10.3)	
Hypertension			
No	2243 (56.7)	123 (62.1)	0.440
Yes	2088 (43.3)	237 (37.9)	
High cholesterol			
No	2653 (62.8)	214 (58.4)	0.468
Yes	1678 (37.2)	146 (41.6)	
BMI			
<18.5 kg/m ²	62 (1.30)	3 (0.21)	0.103
18.5-30.0 kg/m ²	2594 (61.8)	249 (68.6)	
≥ 30.0 kg/m ²	1675 (36.9)	108 (31.2)	
High C-reactive protein			
No	3839 (89.6)	315 (92.6)	0.317
Yes	492 (10.4)	45 (7.40)	
Depressive symptom			
No	3967 (93.0)	337 (90.6)	0.509

Yes	364 (7.05)	23 (9.40)	
Coexisting ocular diseases			
No	3334 (81.5)	204 (84.0)	0.450
Yes	997 (18.5)	156 (16.0)	
Walking disability			
No	3950 (92.8)	300 (91.6)	0.532
Yes	381 (7.20)	60 (8.44)	
Self-rated health			
Poor/Fair	1054 (17.6)	92 (17.1)	0.896
Good/Excellent	3277 (82.4)	268 (82.9)	
History of congestive heart failure			
No	4156 (97.0)	339 (94.2)	0.314
Yes	175 (3.02)	21 (5.76)	
History of heart attack			
No	4094 (95.4)	322 (92.9)	0.424
Yes	237 (4.58)	38 (7.10)	
History of stroke			
No	4157 (96.3)	315 (96.5)	0.802
Yes	174 (3.71)	45 (3.46)	
History of cancer			
No	3818 (88.2)	294 (91.4)	0.198
Yes	513 (11.8)	66 (8.56)	

Abbreviations: AMD, age-related macular degeneration; BMI, body mass index.

^a All P values were calculated using the design-adjusted Rao-Scott Pearson χ^2 test for categorical variables.

273

274

275 Table 2. Risk for All-Cause Mortality and Specific-Cause Mortality in Participants With AMD Compared With Non-AMD After Propensity Score Matching

	All-Cause Mortality		CVD Mortality		Cancer Mortality		Non-CVD/Non-cancer Mortality	
	Events/Number	HR (95% CI) ^a	Events/Number	HR (95% CI) ^a	Events/Number	HR (95% CI) ^a	Events/Number	HR (95% CI) ^a
AMD status								
No AMD	571/4331	Reference	110/4331	Reference	142/4331	Reference	319/4331	Reference
Any AMD	127/360	2.02 (1.37-2.98)	19/360	1.42 (0.69-2.92)	22/360	1.42 (0.72-2.82)	86/360	2.17 (1.39-3.39)
Early AMD	104/318	1.93 (1.31-2.85)	15/318	1.27 (0.58-2.82)	20/318	1.45 (0.73-2.89)	69/318	2.18 (1.36-3.51)
Late AMD	23/42	4.29 (2.10-8.79)	4/42	2.48 (1.32-4.65)	2/42	0.44 (0.06-3.27) ^b	17/42	3.95 (1.65-9.46)

Abbreviations: AMD, age-related macular degeneration; CVD, cardiovascular disease; CI, confidence interval; HR, hazard ratio.

^a Adjusted for age, gender, race, education, marital status, family income, smoking status, alcohol consumption, diabetes mellitus, hypertension, high cholesterol, BMI, high CRP, depressive symptom, coexisting ocular diseases, walking disability, self-rated health, history of cardiovascular diseases, and cancer.

^b Adjusted for age and gender.

Boldface indicates statistical significance.

Acknowledgement

1) **Funding Support:** The present work was supported by the Fundamental Research Funds of the State Key Laboratory of Ophthalmology, National Natural Science Foundation of China (82000901, 82101173), Project of Investigation on Health Status of Employees in Financial Industry in Guangzhou, China (Z012014075), Science and Technology Program of Guangzhou, China (202002020049), the Research Foundation of Medical Science and Technology of Guangdong Province (B2021237). The sponsor or funding organization had no role in the design or conduct of this research.

2) **Financial Disclosures:** None.

3) **Other Acknowledgement:** None.

Author Contributions:

Study concept and design: Yifan Chen, Wei Wang, Zhuoting Zhu;

Acquisition, analysis, or interpretation: Xianwen Shang, Wei Wang, Zhuoting Zhu;

Drafting of the manuscript: Yifan Chen, Yueye Wang;

Critical revision of the manuscript for important intellectual content: Xianwen Shang, Wei Wang, Zhuoting Zhu;

Statistical analysis: Xianwen Shang, Wei Wang, Zhuoting Zhu;

Obtained funding: Wei Wang, Zhuoting Zhu;

Administrative, technical, or material support: Wei Wang, Zhuoting Zhu;

Study supervision: Xianwen Shang, Wei Wang, Zhuoting Zhu;

Abbreviations and Acronyms:

AMD = age-related macular degeneration; anti-VEGF = anti-vascular endothelial growth factor; NHANES = National Health and Nutrition Examination Survey; NCHS = National Center for Health Statistics; ICD-10 = International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; HR = Hazard ratios; CI = confidence interval.

Reference :

1. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5(12):e1221-e1234.
2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health*. 2014;2(2):e106-116.
3. Common Eye Disorders | Basics | VHI | CDC. <https://www.cdc.gov/visionhealth/basics/ced/index.html> (2019).
4. Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S. Societal Costs Associated with Neovascular Age-Related Macular Degeneration in the United States. *Retina*. 2016;36(2):285-298.
5. Clemons TE, Kurinij N, Sperduto RD, Group AR. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. *Arch Ophthalmol*. 2004;122(5):716-726.
6. Fisher DE, Jonasson F, Eiriksdottir G, et al. Age-related macular degeneration and mortality in community-dwelling elders: the age, gene/environment susceptibility Reykjavik study. *Ophthalmology*. 2015;122(2):382-390.
7. Buch H, Vinding T, la Cour M, Jensen GB, Prause JU, Nielsen NV. Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City Eye Study. *Acta Ophthalmol Scand*. 2005;83(4):409-418.
8. Cugati S, Cumming RG, Smith W, Burlutsky G, Mitchell P, Wang JJ. Visual impairment, age-related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study. *Arch Ophthalmol*. 2007;125(7):917-924.
9. Gangnon RE, Lee KE, Klein BE, Iyengar SK, Sivakumaran TA, Klein R. Effect of the Y402H variant in the complement factor H gene on the incidence and progression of age-related macular degeneration: results from multistate models applied to the Beaver Dam Eye Study. *Arch Ophthalmol*. 2012;130(9):1169-1176.
10. Age-Related Eye Disease Study 2 Research G, Papudesu C, Clemons TE, Agron E, Chew EY. Association of Mortality with Ocular Diseases and Visual Impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. *Ophthalmology*. 2018;125(4):512-521.
11. Pedula KL, Coleman AL, Yu F, et al. Age-related macular degeneration and mortality in older women: the study of osteoporotic fractures. *J Am Geriatr Soc*. 2015;63(5):910-917.
12. Gopinath B, Liew G, Burlutsky G, Mitchell P. Age-related macular degeneration and risk of total and cause-specific mortality over 15 years. *Maturitas*. 2016;84:63-67.
13. Siantar RG, Cheng CY, Gemmy Cheung CM, et al. Impact of Visual Impairment and Eye diseases on Mortality: the Singapore Malay Eye Study (SiMES). *Sci Rep*. 2015;5:16304.
14. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. *Arch Ophthalmol*. 2006;124(2):243-249.
15. Xu L, Li YB, Wang YX, Jonas JB. Age-related macular degeneration and mortality: the Beijing eye study. *Ophthalmologica*. 2008;222(6):378-379.
16. McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. *Br J*

- Ophthalmol.* 2001;85(3):322-326.
17. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. *Ophthalmology*. 2003;110(7):1292-1296.
18. Khanna RC, Murthy GV, Giridhar P, et al. Cataract, visual impairment and long-term mortality in a rural cohort in India: the Andhra Pradesh Eye Disease Study. *PLoS One*. 2013;8(10):e78002.
19. Thiagarajan M, Evans JR, Smeeth L, Wormald RP, Fletcher AE. Cause-specific visual impairment and mortality: results from a population-based study of older people in the United Kingdom. *Arch Ophthalmol*. 2005;123(10):1397-1403.
20. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. *Ophthalmology*. 2007;114(1):86-91.
21. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. *Ophthalmology*. 2007;114(6):1143-1150.
22. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. *Ophthalmology*. 2003;110(4):636-643.
23. Delcourt C, Michel F, Colvez A, et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. *Ophthalmic Epidemiol*. 2001;8(4):237-249.
24. Pratt NL, Ramsay EN, Kemp A, et al. Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis. *Drug Saf*. 2014;37(12):1021-1027.
25. Schlenker MB, Thiruchelvam D, Redelmeier DA. Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism. *Am J Ophthalmol*. 2015;160(3):569-580 e565.
26. Zhu Z, Wang W, Keel S, Zhang J, He M. Association of Age-Related Macular Degeneration With Risk of All-Cause and Specific-Cause Mortality in the National Health and Nutrition Examination Survey, 2005 to 2008. *JAMA Ophthalmol*. 2019;137(3):248-257.
27. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res*. 2011;46(3):399-424.
28. Benedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching and its alternatives. *Eur J Cardiothorac Surg*. 2018;53(6):1112-1117.
29. Elze MC, Gregson J, Baber U, et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. *J Am Coll Cardiol*. 2017;69(3):345-357.
30. Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey Data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005. Available at: <http://www.cdc.gov/nchs/nhanes.htm>. Accessed February 11, 2018.
31. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. *Ophthalmology*. 1991;98(7):1128-1134.
32. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related

- maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. *Ophthalmology*. 1999;106(6):1056-1065.
33. Loprinzi PD, Addoh O. Predictive Validity of the American College of Cardiology/American Heart Association Pooled Cohort Equations in Predicting All-Cause and Cardiovascular Disease-Specific Mortality in a National Prospective Cohort Study of Adults in the United States. *Mayo Clin Proc*. 2016;91(6):763-769.
34. McGuinness MB, Finger RP, Karahalios A, et al. Age-related macular degeneration and mortality: the Melbourne Collaborative Cohort Study. *Eye (Lond)*. 2017;31(9):1345-1357.
35. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. *BMC Ophthalmol*. 2010;10:31.
36. Ryu SJ, Lee WJ, Tarver LB, et al. Depressive Symptoms and Quality of Life in Age-related Macular Degeneration Based on Korea National Health and Nutrition Examination Survey (KNHANES). *Korean J Ophthalmol*. 2017;31(5):412-423.
37. Eisenberg-Guyot J, Prins SJ. Relational Social Class, Self-Rated Health, and Mortality in the United States. *Int J Health Serv*. 2020;50(1):7-20.
38. NHANES Survey Methods and Analytic Guidelines. <https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx#analytic-guidelines>.
39. Xin X, Sun Y, Li S, Xu H, Zhang D. AGE-RELATED MACULAR DEGENERATION AND THE RISK OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY: A Meta-Analysis of Cohort Studies. *Retina*. 2018;38(3):497-507.
40. McGuinness MB, Karahalios A, Finger RP, Guymer RH, Simpson JA. Age-Related Macular Degeneration and Mortality: A Systematic Review and Meta-Analysis. *Ophthalmic Epidemiol*. 2017;24(3):141-152.
41. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? *Ophthalmic Epidemiol*. 1999;6(2):125-143.
42. Kishan AU, Modjtahedi BS, Martins EN, Modjtahedi SP, Morse LS. Lipids and age-related macular degeneration. *Surv Ophthalmol*. 2011;56(3):195-213.
43. Hanus J, Anderson C, Wang S. RPE necroptosis in response to oxidative stress and in AMD. *Ageing Res Rev*. 2015;24(Pt B):286-298.
44. Wu J, Uchino M, Sastry SM, Schaumberg DA. Age-related macular degeneration and the incidence of cardiovascular disease: a systematic review and meta-analysis. *PLoS One*. 2014;9(3):e89600.
45. Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. *Eye Vis (Lond)*. 2016;3:34.
46. Beaumont PE, Petocz P, Kang HK. Is there risk of stroke with aflibercept? *Ophthalmology*. 2014;121(1):e4.
47. Kemp A, Preen DB, Morlet N, et al. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. *Retina*. 2013;33(5):920-927.
48. Choi S, Jahng WJ, Park SM, Jee D. Association of Age-Related Macular Degeneration on Alzheimer or Parkinson Disease: A Retrospective Cohort Study. *Am J Ophthalmol*. 2020;210:41-47.
49. Seden D, Alime G, Kadir D, Serpil D, Levent T, Ozlem T. Is Alzheimer disease related to age-related macular degeneration? *Turk J Med Sci*. 2015;45(5):1115-1121.

50. Rong SS, Lee BY, Kuk AK, et al. Comorbidity of dementia and age-related macular degeneration calls for clinical awareness: a meta-analysis. *Br J Ophthalmol*. 2019;103(12):1777-1783.
51. Woo SJ, Park KH, Ahn J, et al. Cognitive impairment in age-related macular degeneration and geographic atrophy. *Ophthalmology*. 2012;119(10):2094-2101.
52. Kulmala J, Era P, Parssinen O, et al. Lowered vision as a risk factor for injurious accidents in older people. *Aging Clin Exp Res*. 2008;20(1):25-30.
53. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. *J Am Geriatr Soc*. 1998;46(1):58-64.
54. Coleman AL, Yu F, Ensrud KE, et al. Impact of age-related macular degeneration on vision-specific quality of life: Follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. *Am J Ophthalmol*. 2010;150(5):683-691.